SanBio : Determination of Terms and Conditions of Stock Options
May 14, 2021 at 11:35 am EDT
Share
May 14, 2021
Company name:
SanBio Co., Ltd.
Representative:
Keita Mori, Representative Director and
President
(TSE Mothers Code: 4592)
Contact:
Yoshihiro Kakutani, Corporate Officer of
Management Administration
(TEL. +81-3-6264-3481)
Determination of Terms and Conditions of Stock Options
(Share Acquisition Rights)
SanBio Company Limited (hereafter, "the Company") hereby announces that the pending terms and conditions of the share acquisition rights, to be issued as part of the Company's stock option program pursuant to the Board of Directors' resolution dated April 28, 2021, have been determined as follows:
The 27th Share Acquisition Rights
1. Total Number of Share Acquisition Rights
12,000 units
Type and Number of Shares Subject to Share Acquisition Rights 12,000 shares of common stock in the Company
Value of the Asset to be Contributed upon Exercise of Share Acquisition Rights 1,683 yen per one unit of Share Acquisition Right (1,683 yen per share)
Persons to whom Share Acquisition Rights are Allocated, the Number of such Persons, and the Number of Share Acquisition Rights Allocated
Persons to whom Share
Number of such Persons
Number of Share Acquisition Rights
Acquisition Rights are
Allocated
Allocated
An Employee of the
Company's Subsidiary (who
1
12,000 units
also Serves as a Director of
the Company)
II The28th Share Acquisition Rights
1. Total Number of Share Acquisition Rights 1,000 units
Type and Number of Shares Subject to Share Acquisition Rights 1,000 shares of common stock in the Company
Value of the Asset to be Contributed upon Exercise of Share Acquisition Rights 1,683 yen per one unit of Share Acquisition Right (1,683 yen per share)
Persons to whom Share Acquisition Rights are Allocated, the Number of such Persons, and the Number of Share Acquisition Rights Allocated
Persons to whom Share
Number of such Persons
Number of Share Acquisition Rights
Acquisition Rights are
Allocated
Allocated
An Employee of the
1
1,000 units
Company
End
Attachments
Original document
Permalink
Disclaimer
SanBio Co. Ltd. published this content on 14 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2021 15:34:17 UTC.
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).